Evidence and New Challenges in Rectal Cancer

08-11 May, 2014
Prague, Czech Republic

Faculty

Course Director:  

Vincenzo Valentini, Radiation Oncologist, Università Cattolica S.Cuore, Rome (IT)

Faculty :

Regina Beets-Tan, Radiologist, University Hospital Maastricht, Maastricht (NL)
Andreas Cervantes, Medical Oncologist, University Hospital of Valencia (ES)
Claudio Coco, Surgeon, Università Cattolica S.Cuore, Rome (IT)
Karin Haustermans, Radiation Oncologists, University Hospital Gasthuisberg, KU-Leuven (BE)
Lars Påhlman, Surgeon, Uppsala University Hospital, Uppsala (SE)
Claus Rödel, Radiation Oncologist, Johann Wolfgang Goethe University, Frankfurt (DE)

Nigel Scott, Pathologist, St James’s University Hospital, Leeds (GB)

Cornelius Van de Velde, Surgeon, Leiden University Medical Center, Leiden (NL)

Delineation Administrator:

Maria Antonietta Gambacorta, Radiation Oncologist, Università Cattolica S.Cuore, Rome (IT)

Local organizer:

Hana Stankusova, Radiation Oncologist, University Hospital Motol, Prague (CZ) 

Course Aim

 

This course, jointly organised by ESTRO, ESSO and ESMO, seeks to promote an integrated approach between all specialists involved in rectal cancer to tailor the best treatment for each individual patient. The most relevant ongoing questions in multidisciplinary management of rectal cancer patients will be addressed by case discussion, open debates and interaction with experts. In a truly multidisciplinary atmosphere, you will be able to identify the major uncertainties of the daily practice and learn how to handle them. You will have the opportunity to design a new research starting from available state of the art evidence.
The presence of colleagues with different specialties from all over the world will enrich your perspective and your daily practice. Don’t miss this chance to encounter the best science in rectal cancer patients’ management.

Target group

The target group consists of surgeons, radiotherapy oncologist, medical oncologists and diagnosticians involved in the multidisciplinary treatment of rectal cancer.

Educational Programme

 

Day 1

  • What we consider innovation vs. state of art the perspective of:

- EURECCA                

- Diagnose                                                                 

- Surgery                                                        

- Pathology

- Radiation Oncology

- Medical Oncology                                                                                

Case discussion                                               

 

Day 2

  • The house believes that for low risk tumour only surgery is enough                                    

- Are there tumours at low risk for local recurrence and mets ?          

- Is imaging reliable to identify low risk tumors?                                  

- Is mucosectomy enough for all cT1 ?                                            

- Is TEM enough for all stage I ?                                                        

- Is TME enough for cT3a/b N0 ?                                                       

- Is radiotherapy helpful for cT3a/b N0 ?                                            

- Is chemotherapy helpful for cT3a/b N0 ?                                          

Discussion

  • Workshops
  • The house believes that for some intermediate risk tumor no surgery is possible

- Are there tumors at intermediate risk for local recurrence and mets ?    

- Is imaging reliable to identify intemediate risk and responders tumors?     

- Can RT replace surgery for intermediate tumor ?                                                  

- Can surgeon recommend no surgery in responder patients ?                                 

- Can medical oncologist recommend no chemotherapy in responders ?              

- Are imaging based models reliable to identify no surgery candidate patients?        

- How to manage aged patients ?                                                                          

Discussion

  • Workshops                                                                           

Day 3

  • The house believes that for high risk tumour intensification is mandatory              

 - Are there tumors at high risk for local recurrence and mets ?                  

- Is imaging reliable to identify high risk tumors?                                       

- How do we intensify radiotherapy in high risk tumors?                              

 - How do we intensify chemotherapy in high risk tumors?                          

- How do we intensify surgery in high risk tumors ?                                  

- Are imaging based models reliable to identify no surgery candidate patients?       

Discussion

  • Workshops                                                                                     
  • The house believes that appropriate use of technology saves life

- How to evaluate the pathological report ?                                                           

- How to evaluate imaging quality?                                                                       

- How to evaluate TME quality ?                                                                            

- How to evaluate endoscopy/robot surgery quality?                                               

- How to evaluate iMRT quality?                                                              

- How to evaluate IGRT quality?                                                              

- How to evaluate Brachy/IORT quality?                                                   

- How to evaluate chemotherapy delivery quality?                                                 

- How to monitor surgery related late side effect?                                                 

- How to monitor radiotherapy related late side effects   

Discussion      

Day 4

  • Workshops                                                                
General debate on ‘New proposal for randomized studies’
news